Citations

Clear

1526 citation(s) found for "Sun, Yu".

Transcriptome and epigenome landscape of human cortical development modeled in organoids
Amiri, Anahita , Coppola, Gianfilippo , Scuderi, Soraya , Wu, Feinan , Roychowdhury, Tanmoy , Liu, Fuchen , Pochareddy, Sirisha , Shin, Yurae , Safi, Alexias , Song, Lingyun , Sousa, André M. M. , Crawford, Gregory E. , Šestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M. , An, Joon‐Yong , Armoskus, Christoper, Beach, Thomas G., Belmont, Judson, Bendl, Jaroslav , Borrman, Tyler , Brown, Leanne, Brown, Miguel , Brown, Mimi, Brunetti, Tonya M. , Burke, Emily E., Chae, Yooree, Charney, Alexander W. , Cherskov, Adriana , Choi, Jinmyung , Clarke, Declan , Valle, Diane M. Del , Devillers, Olivia, Dracheva, Stella , Emani, Prashant S. , Evgrafov, Oleg V. , Fitzgerald, Dominic , Flatow, Elie, Francoeur, Nancy , Fullard, John F. , Gao, Tianliuyun , Geschwind, Daniel H. , Giase, Gina , Goodman, Thomas, Grennan, Kay, Gu, Mengting , Hadjimichael, Evi , Hahn, Chang-Gyu, Haroutunian, Vahram , Huey, Jack , Ivanov, Nikolay A. , Jacobov, Rivka, Jiang, Yan , Jiang, Yi , Kassim, Bibi, Kefi, Amira , Kleiman, Joel E., Knowles, James A. , Kozlenkov, Alexey , Li, Zhen , Lipska, Barbara K., Mangravite, Lara M. , Mariani, Jessica , Mattei, Eugenio , Miller, Daniel J. , Moore, J. Russell, Peters, Mette A. , Pinto, Dalila , Polioudakis, Damon, Ray, Mohana, Reddy, Timothy E. , Rhie, Suhn K. , Santpere, Gabriel , Sheppard, Brooke , Shi, Xu , Shieh, Annie W. , Shin, Joo Heon , Spitsyna, Valeria N. , Szatkiewicz, Jin , Szekely, Anna , Wang, Yongjun , Weissman, Sherman M., Weng, Zhiping , White, Kevin P. , Willsey, Jeremy A., Witt, Heather , Won, Hyejung , Xia, Yan , Xu, Min , Yang, Mo , Zandi, Peter P. , Zhang, Jing , Zharovsky, Elizabeth , Sousa, André M M , Gerstein, Mark , Crawford, Gregory E , Sestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M , Del Valle, Diane M , Zhu, Ying , Gerstein, Mark , Akbarian, Schahram , Ashley‐Koch, Allison E. , Bryois, Julien , Camarena, Adrian , Carlyle, Becky Catherine , Chen, Chao , Cheng, Lijun , Collado‐Torres, Leonardo , Dai, Rujia , Torre-Ubieta, Luis de la , Farnham, Peggy , Gandal, Michael J. , Garrett, Melanie E , Girdhar, Kiran Kumar , Giusti‐Rodríguez, Paola , Goes, Fernando , Goodman, Thomas, Gürsoy, Gamze , Hauberg, Mads E. , Hoffman, Gabriel E. , Hyde, Thomas M , Jaffe, Andrew E. , Johnson, Graham D. , Kim, Yunjung , Kitchen, Robert , Li, Mingfeng , Liu, Chunyu , Liu, Shuang , Moore, Jill, Nairn, Angus C. , Navarro, Fábio C. P. , Park, Royce , Pratt, Henry , Price, Amanda J. , Purcaro, Michael J. , Roussos, Panos , Sanders, Stephan , Schreiner, Shannon , Škarica, Mario , State, Matthew W. , Sullivan, Patrick F. , Swarup, Vivek , Tao, Ran , Bakel, Harm van , Wang, Daifeng , Warrell, Jonathan , Webster, Maree J. , Werling, Donna M. , Wiseman, Jennifer R. , Wray, Gregory A. , Yang, Yucheng

Mayo Clinic

Science | December 13, 2018 | Volume: 362 | Issue: 6420 | Pages: No page available

10.1126/science.aat6720 | PMID 30545853 Get It

INTRODUCTION The human cerebral cortex has undergone an extraordinary increase in size and complexity during mammalian evolution. Cortical cell lineages are specified in the embryo, and genetic and epidemiological evidence implicates early cortical development in the etiology of neuropsychiatric disorders such as autism spectrum disorder (ASD), intellectual disabilities, and schizophrenia. Most of the disease-implicated genomic variants are located outside of genes, and the interpretation of noncoding mutations is lagging behind owing to limited annotation of functional elements in the noncoding genome. RATIONALE We set out to discover gene-regulatory elements and chart their dynamic activity during prenatal human cortical development, focusing on enhancers, which carry most of the weight upon regulation of gene expression. We longitudinally modeled human brain development using human induced pluripotent stem cell (hiPSC)–derived cortical organoids and compared organoids to isogenic fetal brain tissue. RESULTS Fetal fibroblast–derived hiPSC lines were used to generate cortically patterned organoids and to compare oganoids’ epigenome and transcriptome to that of isogenic fetal brains and external datasets. Organoids model cortical development between 5 and 16 postconception weeks, thus enabling us to study transitions from cortical stem cells to progenitors to early neurons. The greatest changes occur at the transition from stem cells to progenitors. The regulatory landscape encompasses a total set of 96,375 enhancers linked to target genes, with 49,640 enhancers being active in organoids but not in mid-fetal brain, suggesting major roles in cortical neuron specification. Enhancers that gained activity in the human lineage are active in the earliest stages of organoid development, when they target genes that regulate the growth of radial glial cells. Parallel weighted gene coexpression network analysis (WGCNA) of transcriptome and enhancer activities defined a number of modules of coexpressed genes and coactive enhancers, following just six and four global temporal patterns that we refer to as supermodules, likely reflecting fundamental programs in embryonic and fetal brain. Correlations between gene expression and enhancer activity allowed stratifying enhancers into two categories: activating regulators (A-regs) and repressive regulators (R-regs). Several enhancer modules converged with gene modules, suggesting that coexpressed genes are regulated by enhancers with correlated patterns of activity. Furthermore, enhancers active in organoids and fetal brains were enriched for ASD de novo variants that disrupt binding sites of homeodomain, Hes1, NR4A2, Sox3, and NFIX transcription factors. CONCLUSION We validated hiPSC-derived cortical organoids as a suitable model system for studying gene regulation in human embryonic brain development, evolution, and disease. Our results suggest that organoids may reveal how noncoding mutations contribute to ASD etiology. Summary of the study, analyses, and main results. Data were generated for iPSC-derived human telencephalic organoids and isogenic fetal cortex. Organoids modeled embryonic and early fetal cortex and show a larger repertoire of enhancers. Enhancers could be divided into activators and repressors of gene expression. We derived networks of modules and supermodules with correlated gene and enhancer activities, some of which were implicated in autism spectrum disorders (ASD).
High‐Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network
Fudim, Marat , Ambrosy, Andrew P. , Sun, Jie‐Lena , Anstrom, Kevin J. , Bart, Bradley A. , Butler, Javed , AbouEzzeddine, Omar F. , Greene, Stephen J. , Mentz, Robert J. , Redfield, Margaret M. , Reddy, Yogesh N.V. , Borlaug, Barry A. , Felker, G. Michael , AbouEzzeddine, Omar, Nishimura, Rick , Borlaug, Barry A , Mentz, Robert J , Vaduganathan, Muthiah , Braunwald, Eugene , Hernandez, Adrian F. , AbouEzzeddine, Omar F

Mayo Clinic

Journal of the American Heart Association | December 7, 2018 | Volume: 7 | Issue: 24 | Pages: No page available

10.1161/jaha.118.010364 | PMID 30561266 Get It

Background We sought to study the prevalence of high‐sensitivity troponin and its association with cardiac structure and outcomes in ambulatory and hospitalized patients with heart failure with a preserved ejection fraction ( HF p EF ). Methods and Results A post hoc analysis utilized data from HF p EF patients: DOSE (Diuretic Optimization Strategies Evaluation) and CARRESS ‐ HF (Cardiorenal Rescue Study in Acute Decompensated Heart Failure) enrolled patients hospitalized with acute HF p EF , and RELAX (Phosphodiesterase‐5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With Preserved Ejection Fraction) enrolled ambulatory patients with HF p EF . High‐sensitivity troponin I (hs‐TnI) was measured in hospitalized patients at baseline, at 72 to 96 hours, on day 7, and on day 60. In ambulatory patients hs‐TnI was measured at baseline and at week 24. In the ambulatory cohort, correlations between hs‐TnI and cardiac structure and function were assessed. The association between hs‐TnI and a 60‐day composite of emergency room visits, readmissions, and death was assessed for hospitalized patients using multivariable Cox proportional hazard models. The study population included 139 hospitalized and 212 ambulatory patients with HF p EF and hs‐TnI measured at baseline. The median (25th, 75th percentiles) baseline troponin was 17.6 (11.1, 41.0) ng/L in hospitalized patients and 9.5 (5.3, 19.7) ng/L in ambulatory patients ( P <0.001). The prevalence of elevated hs‐TnI (>99% percentile upper reference limit was 86% in hospitalized patients and 53% among ambulatory patients, with stable elevation in ambulatory patients during follow‐up. HF p EF patients with a hs‐TnI above the median were older with worse left ventricular hypertrophy and diastolic dysfunction. Continuously valued hs‐TnI (per doubling) was associated with increased risk of composite end point (adjusted hazard ratio 1.20, 95% confidence interval 1.00‐1.43; P =0.042). Conclusions Hs‐TnI is commonly elevated among both hospitalized and ambulatory patients with HF p EF . Increased hs‐TnI levels are associated with worse cardiac structure and increased risk of adverse events.
Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features
Wu, Jiang , Cai, Muyan , Li, Shiyong , Bei, Jin‐Xin , Wang, Fang , Ling, Yihong , Rodrı́guez-Bigas, Miguel A. , Dignam, James J. , Mao, Mao , Li, Jibin , Guo, Yun‐Miao , Wu, Xiaoyan , Kong, Lingheng , Tang, Jing‐Hua, Li, Chao‐Feng, Chen, Jie‐Rong, Ye, Ming‐Zhi, Guo, Fengming, Han, Peng , Wan, Desen, Li, Li , Xu, Rui‐Hua , Ding, Pei-Rong , Group, Written on behalf of AME Colorectal Cancer Cooperative, Xu, Rui‐Hua , Jiang, Wu , Xu, Rui-Hua , Hampel, Heather , Frayling, Ian M. , Sinicrope, Frank A. , Kerr, David , Rosell, Rafael , Kong, Ling‐Heng, Tang, Jing-Hua , Wu, Xiaodan , Ou, Qingjian , Ye, Ming-Zhi, Wang, Qiwei , Pan, Zhizhong , Group, Written on behalf of AME Colorectal Cancer Cooperative

Mayo Clinic

International Journal of Cancer | December 6, 2018 | Volume: 144 | Issue: 9 | Pages: 2161-2168

10.1002/ijc.32044 | PMID 30521064 Get It

The prevalence of Lynch syndrome (LS) varies significantly in different populations, suggesting that ethnic features might play an important role. We enrolled 3330 consecutive Chinese patients who had surgical resection for newly diagnosed colorectal cancer. Universal screening for LS was implemented, including immunohistochemistry for mismatch repair (MMR) proteins, BRAFV600E mutation test and germline sequencing. Among the 3250 eligible patients, MMR protein deficiency (dMMR) was detected in 330 (10.2%) patients. Ninety‐three patients (2.9%) were diagnosed with LS. Nine (9.7%) patients with LS fulfilled Amsterdam criteria II and 76 (81.7%) met the revised Bethesda guidelines. Only 15 (9.7%) patients with absence of MLH1 on IHC had BRAFV600E mutation. One third (33/99) of the MMR gene mutations have not been reported previously. The age of onset indicates risk of LS in patients with dMMR tumors. For patients older than 65 years, only 2 patients (5.7%) fulfilling revised Bethesda guidelines were diagnosed with LS. Selective sequencing of all cases with dMMR diagnosed at or below age 65 years and only of those dMMR cases older than 65 years who fulfill revised Bethesda guidelines results in 8.2% fewer cases requiring germline testing without missing any LS diagnoses. While the prevalence of LS in Chinese patients is similar to that of Western populations, the spectrum of constitutional mutations and frequency of BRAFV600E mutation is different. Patients older than 65 years who do not meet the revised Bethesda guidelines have a low risk of LS, suggesting germline sequencing might not be necessary in this population.
A Review on Electroporation-Based Intracellular Delivery
Shi, Junfeng, Ma, Yifan , Zhu, Jing , Chen, Yuanxin , Sun, Yating , Yao, Yicheng, Yang, Zhaogang , Xie, Jing

Mayo Clinic

Molecules | November 22, 2018 | Volume: 23 | Issue: 11 | Pages: 3044

10.3390/molecules23113044 | PMID 30469344 Get It

Intracellular delivery is a critical step in biological discoveries and has been widely utilized in biomedical research. A variety of molecular tools have been developed for cell-based gene therapies, including FDA approved CAR-T immunotherapy, iPSC, cell reprogramming and gene editing. Despite the inspiring results of these applications, intracellular delivery of foreign molecules including nucleic acids and proteins remains challenging. Efficient yet non-invasive delivery of biomolecules in a high-throughput manner has thus long fascinates the scientific community. As one of the most popular non-viral technologies for cell transfection, electroporation has gone through enormous development with the assist of nanotechnology and microfabrication. Emergence of miniatured electroporation system brought up many merits over the weakness of traditional electroporation system, including precise dose control and high cell viability. These new generation of electroporation systems are of considerable importance to expand the biological applications of intracellular delivery, bypassing the potential safety issue of viral vectors. In this review, we will go over the recent progresses in the electroporation-based intracellular delivery and several potential applications of cutting-edge research on the miniatured electroporation, including gene therapy, cellular reprogramming and intracellular probe.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Harrell, Maria I., Oza, Amit M. , Oaknin, Ana , Tinker, Anna V. , Helman, Elena , Radke, Marc R. , Say, Carmen , Vo, Lan-Thanh, Mann, Elaina, Isaacson, Jeffrey D., Maloney, Lara , O’Malley, David M. , Chambers, Setsuko K., Scott, Clare L. , Konecny, Gottfried E. , Giordano, Heidi, Harding, Thomas C., McNeish, Iain A. , Swisher, Elizabeth M. , Lin, Kevin K. , Kaufmann, Scott H , Brenton, James D , McNeish, Iain A , Swisher, Elizabeth M , Scott, Clare L , O'Malley, David M , Lin, Kevin , Ray-Coquard, Isabelle L. , Kaufmann, Scott H. , Coleman, Robert L. , Sun, James X. , Brenton, James D.

Mayo Clinic

Cancer Discovery | November 13, 2018 | Volume: 9 | Issue: 2 | Pages: 210-219

10.1158/2159-8290.cd-18-0715 | PMID 30425037 Get It

Abstract A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC), we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib. BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049). Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P &lt; 0.0001). To study acquired resistance, we sequenced 78 postprogression cfDNA, identifying eight additional patients with BRCA reversion mutations not found in pretreatment cfDNA. Significance: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment. Sequencing of cfDNA can detect multiple BRCA reversion mutations, highlighting the ability to capture multiclonal heterogeneity. This article is highlighted in the In This Issue feature, p. 151
Author response: Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer
Liao, Lili, Langbein, Lauren , Cho, Eun-Ah , Niu, Xiaohua , Jiang, Wei , Zhong, Zhijiu , Jagannathan, Geetha , Dulaimi, Essel, Testa, Joseph R. , Wang, Yuxin , Stark, George R. , Peiper, Stephen, Yang, Haifeng , Liu, Zongzhi Z. , Cai, Weijia , Na, Jie, Cai, Wesley L. , Uzzo, Robert G. , Sun, Jianxin , Xu, Yaomin , Yan, Qin

Mayo Clinic

No container title available | November 12, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.37925.029 Get It

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
Chhabra, Saurabh , Ahn, Kwang Woo , Hu, Zhen‐Huan , Jain, Sandeep , Černý, Jan , Copelan, Edward A. , Daly, Andrew , DeFilipp, Zachariah , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hamilton, Betty K. , Hildebrandt, Gerhard , Hsu, Jack W., Inamoto, Yoshihiro , Kanate, Abraham S. , Khoury, H. Jean, Litzow, Mark R. , Nathan, Sunita , Olsson, Richard F. , Pawarode, Attaphol , Ringdén, Olle , Rowe, Jacob M. , Saad, Ayman , Schouten, Harry C. , Seo, Sachiko , Shah, Nirav N. , Solh, Melhem , Üstün, Celalettin , Woolfrey, Ann E. , Alyea, Edwin P. , Kalaycio, Matt, Sobecks, Ronald , Saber, Wael , Cerny, Jan , Gadalla, Shahinaz M , Nathan, Sunita , Saad, Ayman , Olsson, Richard F , Ringden, Olov , Chhabra, Saurabh , Assal, Amer , Gale, Robert Peter , Lazarus, Hillard M. , Savani, Bipin N. , Stuart, Robert K. , Yared, Jean A. , Popat, Uday R

Mayo Clinic

Blood Advances | November 5, 2018 | Volume: 2 | Issue: 21 | Pages: 2922-2936

10.1182/bloodadvances.2018024844 | PMID 30396912 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era.
Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis
Gu, Dongsheng , Lin, Hai , Zhang, Xiaoli , Fan, Qipeng, Chen, Shaoxiong , Shahda, Safi, Xie, Jingwu , Liu, Yunlong , Sun, Jie

Mayo Clinic

Cancers | October 26, 2018 | Volume: 10 | Issue: 11 | Pages: 403

10.3390/cancers10110403 | PMID 30373214 Get It

Pancreatic cancer, mostly pancreatic ductal adenocarcinoma (PDAC), is one of the most lethal cancer types, with an estimated 44,330 death in 2018 in the US alone. While targeted therapies and immune checkpoint inhibitors have significantly improved treatment options for patients with lung cancer and renal cell carcinomas, little progress has been made in pancreatic cancer, with a dismal 5-year survival rate currently at ~8%. Upon diagnosis, the majority of pancreatic cancer cases (~80%) are already metastatic. Thus, identifying ways to reduce pancreatic cancer metastasis is an unmet medical need. Furthermore, pancreatic cancer is notorious resistant to chemotherapy. While Kirsten RAt Sarcoma virus oncogene (K-RAS) mutation is the major driver for pancreatic cancer, specific inhibition of RAS signaling has been very challenging, and combination therapy is thought to be promising. In this study, we report that combination of hedgehog (Hh) and Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) signaling inhibitors reduces pancreatic cancer metastasis in mouse models. In mouse models of pancreatic cancer metastasis using human pancreatic cancer cells, we found that Hh target gene Gli1 is up-regulated during pancreatic cancer metastasis. Specific inhibition of smoothened signaling significantly altered the gene expression profile of the tumor microenvironment but had no significant effects on cancer metastasis. By combining Hh signaling inhibitor BMS833923 with RAS downstream MEK signaling inhibitor AZD6244, we observed reduced number of metastatic nodules in several mouse models for pancreatic cancer metastasis. These two inhibitors also decreased cell proliferation significantly and reduced CD45+ cells (particularly Ly6G+CD11b+ cells). We demonstrated that depleting Ly6G+ CD11b+ cells is sufficient to reduce cancer cell proliferation and the number of metastatic nodules. In vitro, Ly6G+ CD11b+ cells can stimulate cancer cell proliferation, and this effect is sensitive to MEK and Hh inhibition. Our studies may help design novel therapeutic strategies to mitigate pancreatic cancer metastasis.
Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer
Liao, Lili, Langbein, Lauren , Cho, Eun-Ah , Niu, Xiaohua , Jiang, Wei , Zhong, Zhijiu , Cai, Wesley L. , Jagannathan, Geetha , Dulaimi, Essel, Testa, Joseph R. , Uzzo, Robert G. , Wang, Yuxin , Stark, George R. , Peiper, Stephen C., Yan, Qin , Yang, Haifeng , Langbein, Lauren , Na, Jie , Xu, Yaomin , Yan, Qin , Yang, Haifeng , Liu, Zongzhi Z. , Cai, Weijia , Na, Jie, Sun, Jianxin

Mayo Clinic

eLife | October 25, 2018 | Volume: 7 | Issue: No issue available | Pages: No page available

10.7554/elife.37925 | PMID 30355451 Get It

Whereas VHL inactivation is a primary event in clear cell renal cell carcinoma (ccRCC), the precise mechanism(s) of how this interacts with the secondary mutations in tumor suppressor genes, including PBRM1 , KDM5C / JARID1C , SETD2 , and/or BAP1 , remains unclear. Gene expression analyses reveal that VHL, PBRM1, or KDM5C share a common regulation of interferon response expression signature. Loss of HIF2α, PBRM1, or KDM5C in VHL-/- cells reduces the expression of interferon stimulated gene factor 3 (ISGF3), a transcription factor that regulates the interferon signature. Moreover, loss of SETD2 or BAP1 also reduces the ISGF3 level. Finally, ISGF3 is strongly tumor-suppressive in a xenograft model as its loss significantly enhances tumor growth. Conversely, reactivation of ISGF3 retards tumor growth by PBRM1-deficient ccRCC cells. Thus after VHL inactivation, HIF induces ISGF3, which is reversed by the loss of secondary tumor suppressors, suggesting that this is a key negative feedback loop in ccRCC.